# CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

> **NCT01134575** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 90 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** CMC-544 (Inotuzumab Ozogamycin)
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01134575
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-04
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-04-18
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134575, "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01134575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*